By HotStockRockets | Tuesday 7 March 2017
Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Amryt (AMYT) has announced that it has completed of discussions with the Food and Drug Administration, the US FDA, and European Medicines Agency regarding the design of its pivotal phase 3 clinical trial for AP101 as a potential treatment for Epidermolysis Bullosa. The global market for a treatment for EB is, according to Amryt, worth £1.3 billion.
Filed under:
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Time left: 06:52:05